NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research reissued their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report issued on Wednesday,Benzinga reports. BTIG Research currently has a $25.00 target price on the stock.

NRXP has been the subject of a number of other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, January 21st. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. Ascendiant Capital Markets reissued a “buy” rating and set a $48.00 target price (up previously from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. Finally, Zacks Research lowered NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. Four equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $36.75.

NRx Pharmaceuticals Stock Down 1.4%

Shares of NRx Pharmaceuticals stock opened at $1.78 on Wednesday. The business has a fifty day simple moving average of $2.19 and a 200-day simple moving average of $2.56. The firm has a market cap of $52.55 million, a price-to-earnings ratio of -0.76 and a beta of 1.91. NRx Pharmaceuticals has a fifty-two week low of $1.58 and a fifty-two week high of $3.84.

Institutional Trading of NRx Pharmaceuticals

Several large investors have recently modified their holdings of NRXP. Ethos Financial Group LLC bought a new position in NRx Pharmaceuticals in the 3rd quarter worth $39,000. Sjbenen Advisory LLC bought a new position in NRx Pharmaceuticals in the 4th quarter worth approximately $41,000. One Wealth Management Investment & Advisory Services LLC lifted its holdings in shares of NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after buying an additional 12,950 shares during the last quarter. Global Retirement Partners LLC acquired a new position in NRx Pharmaceuticals during the 4th quarter valued at $107,000. Finally, Two Sigma Investments LP boosted its holdings in NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares during the period. 4.27% of the stock is owned by institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.